MAX Chat
Share chart Biogen
Extended chart
Simple chart
Main settings
Currency
usd
Dividend income of JSC
16.3
Dividend of JSC
22.23
IPO Time
1991-09-16
ISIN
US09062X1037
Industry
Biotechnology
Report Currency
usd
Sector
Health Care
Website
Grade
Underestimation
| Title | Value | Grade |
| P/S | 2.26 | 6 |
| P/BV | 1.31 | 9 |
| P/E | 13.43 | 8 |
Efficiency
| Title | Value | Grade |
| ROA | 5.95 | 2 |
| ROE | 10.36 | 4 |
| ROIC | 8.77 | 3 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0.5 | 5 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | 2.34 | 6 |
| Debt/Ratio | 0.2364 | 10 |
| Debt/Equity | 0.678 | 9 |
Growth impulse
| Title | Value | Grade |
| Revenue, bln, % | -28.01 | 0 |
| Ebitda, % | -41.17 | 0 |
| EPS, % | -54.89 | 0 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 144.86 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Week | 141.35 $ | 142.61 $ | 148.84 $ | +2.48 % | 0 % | 0 % |
| Month | 139.31 $ | 132.22 $ | 148.84 $ | +3.98 % | 0 % | 0 % |
| Three month | 135.33 $ | 122.68 $ | 148.84 $ | +7.04 % | 0 % | 0 % |
| Half a year | 117.21 $ | 113.38 $ | 148.84 $ | +23.59 % | 0 % | 0 % |
| Year | 149.9 $ | 113.38 $ | 201.44 $ | -3.36 % | 0 % | 0 % |
| 3 years | 274.72 $ | 113.38 $ | 324.5 $ | -47.27 % | 0 % | 0 % |
| 5 years | 396.64 $ | 113.38 $ | 422.32 $ | -63.48 % | 0 % | 0 % |
| 10 years | 270.85 $ | 113.38 $ | 422.32 $ | -46.52 % | 0 % | 0 % |
| Year to date | 140.19 $ | 113.38 $ | 153.27 $ | +3.33 % | 0 % | 0 % |
Insider trading
Main owners
Contained in ETF
ETF | Share, % | Profitability for 1 year, % | Commission, % |
| PSYK ETF | 4.07 | 0 | 0.75 |
| Future Tech ETF | 2.81727 | 479.5 | 0.35 |
| Principal Healthcare Innovators ETF | 2.81727 | -3.92 | 0.35 |
| IQ U.S. Mid Cap R&D Leaders ETF | 2.48 | 0 | 0.16 |
| John Hancock Multifactor Healthcare ETF | 2.34 | 29.34 | 0.40 |
| iShares Evolved U.S. Innovative Healthcare ETF | 2.29 | 0.000586 | 0.18 |
| Invesco S&P 500® Equal Weight Health Care ETF | 1.77 | 815.08 | 0.40 |
| Nationwide Maximum Diversification U.S. Core Equity ETF | 1.52 | 26.65 | 0.34 |
| IQ Engender Equality ETF | 1.05205 | 1.27 | 0.45 |
| Knowledge Leaders Developed World ETF | 0.91244 | 0.5628 | 0.75 |
| JPMorgan Corporate Bond Research Enhanced ETF | 0.32 | 2.19 | 0.09 |
| iShares Morningstar Mid-Cap ETF | 0.26833 | 229.67 | 0.04 |
| Nationwide Nasdaq-100 Risk-Managed Income ETF | 0.19851 | 3.36 | 0.68 |
| JPMorgan U.S. Aggregate Bond ETF | 0.18 | 3.71 | 0.07 |
| iShares Morningstar Large-Cap Value ETF | 0.11151 | 50.52 | 0.25 |
| Columbia U.S. ESG Equity Income ETF | 0.10133 | -3.61 | 0.35 |
| iShares Morningstar Large-Cap ETF | 0.05802 | 181.01 | 0.03 |
| 1.37 | 106.78 | 0.33 |
|---|
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Ms. Robin C. Kramer | Senior VP & Chief Accounting Officer | N/A | 1966 (59 years) |
| Ms. Natacha Gassenbach | Chief Communication Officer & Head of Corporate Affairs | N/A | |
| Ms. Nicole Murphy | Head of Pharmaceutical Operations & Technology | 1.46M | 1973 (52 years) |
| Mr. Michael R. McDonnell CPA | Executive VP & CFO | 2.12M | 1964 (61 year) |
| Ms. Susan H. Alexander Esq. | Executive VP & Chief Legal Officer | 2.2M | 1957 (68 years) |
| Mr. Christopher A. Viehbacher | President, CEO & Director | 487.94k | 1961 (64 years) |
| Mr. Charles E. Triano | Senior VP & Head of Investor Relations | N/A | |
| Mr. Adam Keeney Ph.D. | Executive VP & Head of Corporate Development | N/A | 1977 (48 years) |
| Mr. Rachid Izzar | Head of Global Product Strategy & Commercialization | 1975 (50 years) | |
| Dr. Ginger Gregory Ph.D. | Executive VP & Chief Human Resources Officer | 1968 (57 years) |
About company
Address: United States, Cambridge, 225 Binney Street - Open in google maps, Open in yandex maps
Website: http://www.biogen.com
Website: http://www.biogen.com
About Biogen
Biogen Inc. — американская многонациональная биотехнологическая компания, базирующаяся в Кембридже, штат Массачусетс, специализирующаяся на открытии, разработке и поставке методов лечения нейродегенеративных, гематологических и аутоиммунных заболеваний пациентам во всем мире.
